Cureus . COVID-19 Associated Coagulopathy in the Setting of Underlying Malignancy

[tetano]

Cureus


. 2020 Aug 28;12(8):e10095.
doi: 10.7759/cureus.10095.
COVID-19 Associated Coagulopathy in the Setting of Underlying Malignancy


Su Lin Lim ¹ , Kok Hoe Chan ¹ , Jihad Slim ² , Gunwant Guron ³ , Hamid S Shaaban ³



Affiliations

• PMID: 33005516
• PMCID: PMC7522179
• DOI: 10.7759/cureus.10095

Abstract

Coronavirus disease 2019 (COVID-19) associated coagulopathy is a well-recognized predictor for morbidity and mortality in COVID-19 patients. Both deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in COVID-19 patients. Nonetheless, there are no consensus guidelines on the use of therapeutic coagulation in this group of patients. We herein present a unique case of a confirmed COVID-19 patient with metastatic ovarian cancer who presented with DVT and PE despite being on therapeutic anticoagulation, highlighting the unpredictability of COVID-19 associated coagulopathy. This case study raises the awareness that the thrombophilic state in metastatic malignancies is potentially augmented by COVID-19. We also discuss the complexity of making anticoagulation treatment decision in COVID-19 patients in the absence of evidence-based guidelines.

Keywords: covid-19 associated coagulopathy; deep venous thrombosis; metastatic ovarian cancer; pulmonary embolism.